CD276 and prostate cancer: Concurrently, although there is a loss of B7-H3 protein in prostate cancers with neuroendocrine differentiation phenotype, B7-H3 is expressed in the vast majority of prostate cancer patients, including those with neuroendocrine characteristics (112).